RESUMEN
BACKGROUND & AIMS: Impact of micronutrient deficiency on childhood malignancy is unexplored. We estimated the prevalence of baseline micronutrient deficiency in children with cancer and its impact on event-free survival (EFS) and overall survival (OS). METHODS: A longitudinal cohort study was conducted at a tertiary cancer centre in India. Children (≤18 years) with de novo malignancy were enrolled between October 2012 and May 2014. Baseline levels of vitamin B12, folate, zinc, selenium, copper, and iron were measured and values below 150 pmol/L, 6 ng/mL, International Zinc Nutrition Collaborative Group cut-off, 0.5 µmol/L, 10 µmol/L, and 50 µg/dL, respectively, indicated deficiency. RESULTS: Total 535 children [326 (60.9%) haematological and 209 (39.1%) solid malignancies] were enrolled with median follow-up of 66 months. Vitamin B12, folate, zinc, selenium, copper and iron deficiencies were found in 209 (39.1%), 89 (16.6%), 173 (32.3%), 39 (7.3%), 12 (2.2%), and 231 (43.2%) children, respectively. Selenium deficiency independently predicted poor EFS (hazard ratio [HR] = 1.56; p = 0.038) and OS (HR = 1.65; p = 0.027) in the cohort. In haematological malignancies, selenium deficiency predicted poor EFS (HR = 1.81; p = 0.023) and OS (HR = 2.12; p = 0.004). In solid malignancies, vitamin B12 (HR = 1.55; p = 0.028) and zinc (HR = 1.74; p = 0.009) deficiencies predicted poor EFS, and zinc deficiency predicted poor OS (HR = 1.77; p = 0.009). Multiple micronutrient (≥3) deficiencies also predicted poor EFS (HR = 1.69; p = 0.001) and OS (HR = 1.83; p < 0.001) in the whole cohort. CONCLUSIONS: Selenium deficiency was independently predictive of adverse outcomes in childhood cancer, particularly in haematological malignancies. Zinc deficiency adversely affected solid tumours. The adjunct use of micronutrient supplementation in paediatric malignancies should be explored.
Asunto(s)
Neoplasias Hematológicas , Desnutrición , Neoplasias , Selenio , Niño , Cobre , Ácido Fólico , Humanos , Estudios Longitudinales , Desnutrición/epidemiología , Micronutrientes , Neoplasias/epidemiología , Prevalencia , Estudios Prospectivos , Vitamina B 12 , Vitaminas , ZincRESUMEN
India has made significant improvement in childhood cancer services in last few decades. However, the outcome still remains modest as compared to global standards due to significant barriers in recognition, diagnosis and cure. Data regarding comprehensive childhood cancer burden in country is lacking due to low and urban predominant coverage of population-based cancer registry programs. The available data shows lower incidence of childhood cancer incidence especially in leukaemia and CNS tumours which may suggest poor awareness of caregivers and delayed diagnosis with many "missed cases". Incidence data are also skewed towards male preponderance which suggests gender bias in seeking healthcare. The childhood cancer services in India are predominantly restricted to few tertiary care centres in major cities. The outcome in major groups of cancer is complicated by delayed and more advanced stage of presentation and poor supportive care during intensive treatment. Treatment refusal and abandonment remains major hurdles. Last few decades saw development of dedicated paediatric oncology services and training programs in the country. The development of InPOG (Indian Paediatric Oncology group) for conducting collaborative trials will lead to adoption of uniform treatment protocols suited for the country. Financial support through the government promoted health insurance and holistic support through philanthropic organizations have improved treatment adherence and outcome. Moving forward, the focus should be on strengthening the cancer registries for capturing nationwide data, improving awareness of childhood cancer among caregivers and healthcare workers for early recognition and improving accessibility of childhood cancer care services beyond major cities.
Asunto(s)
Neoplasias/epidemiología , Neoplasias/terapia , Adolescente , Niño , Preescolar , Femenino , Accesibilidad a los Servicios de Salud , Humanos , Incidencia , India/epidemiología , Lactante , Recién Nacido , Masculino , Sistema de RegistrosAsunto(s)
COVID-19 , Terapias Complementarias , Medicina , Pueblo Asiatico , Humanos , Pandemias , SARS-CoV-2RESUMEN
Aljitawi OS, Paul S, Ganguly A, Lin TL, Ganguly S, Vielhauer G, Capitano ML, Cantilena A, Lipe B, Mahnken JD, Wise A, Berry A, Singh AK, Shune L, Lominska C, Abhyankar S, Allin D, Laughlin M, McGuirk JP, Broxmeyer HE. (Division of Hematologic Malignancies and Cellular Therapy; Hematology and Transplantation Translational Research Laboratory ; Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; Division of Hematology/Oncology and Bone Marrow Transplantation Program, University of Rochester Medical Center, Rochester, New York; Department of Urology, University of Kansas Medical Center, Kansas City, Kansas; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana; Cardiovascular Research Institute, Department of Biostatistics, Department of Radiation Oncology, Department of Emergency Medicine, University of Kansas Medical Center, Kansas City, Kansas; Cleveland Cord Blood Center, Cleveland, Ohio; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.) Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. Blood 2016;128:3000-10.
Asunto(s)
Sangre Fetal , Oxigenoterapia Hiperbárica , Aloinjertos/fisiología , Aloinjertos/trasplante , Plaquetas , Sangre Fetal/fisiología , Sangre Fetal/trasplante , Neoplasias Hematológicas/terapia , Humanos , NeutrófilosAsunto(s)
Crisis Blástica , Leucemia Bifenotípica Aguda , Leucemia Mieloide Aguda , Crisis Blástica/genética , Crisis Blástica/metabolismo , Crisis Blástica/patología , Niño , Preescolar , Femenino , Humanos , Lactante , Leucemia Bifenotípica Aguda/genética , Leucemia Bifenotípica Aguda/metabolismo , Leucemia Bifenotípica Aguda/patología , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/metabolismo , Leucemia Mieloide Aguda/patología , MasculinoRESUMEN
Fusarium species are ubiquitously present in environment and are well known as human pathogens with high mortality rate in immunocompromised patients. We report here two cases where immunocompromised patients developed fatal bloodstream infections by this organism. Isolates were further identified by ITS1 region sequencing which confirmed them as Fusarium solani. Antifungal susceptibility testing was done following CLSI M38-A2 guidelines to amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and micafungin. Both patients had a fatal outcome and expired of septic shock. Therefore, identification up to species level is of utmost importance as that helps in directing the management of the patient thereby leading to a favourable outcome.
Asunto(s)
Antifúngicos/uso terapéutico , Fungemia/mortalidad , Fusariosis/tratamiento farmacológico , Fusariosis/mortalidad , Fusarium/efectos de los fármacos , Choque Séptico/microbiología , Adolescente , Anciano , Anfotericina B/uso terapéutico , Secuencia de Bases , ADN Intergénico/genética , Fluconazol/uso terapéutico , Fungemia/tratamiento farmacológico , Fungemia/microbiología , Fusariosis/microbiología , Humanos , Huésped Inmunocomprometido , India , Masculino , Pruebas de Sensibilidad Microbiana , Análisis de Secuencia de ADN , Choque Séptico/mortalidadAsunto(s)
Adenocarcinoma Sebáceo/tratamiento farmacológico , Cisplatino/uso terapéutico , Neoplasias de los Párpados/tratamiento farmacológico , Fluorouracilo/uso terapéutico , Neoplasias Orbitales/tratamiento farmacológico , Adenocarcinoma Sebáceo/diagnóstico por imagen , Adenocarcinoma Sebáceo/patología , Evisceración del Ojo , Neoplasias de los Párpados/diagnóstico por imagen , Neoplasias de los Párpados/patología , Humanos , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Invasividad Neoplásica , Procedimientos Quirúrgicos Oftalmológicos , Neoplasias Orbitales/diagnóstico por imagen , Neoplasias Orbitales/patología , Radioterapia Adyuvante , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of chemotherapy. Ginger has been used in postoperative and pregnancy-induced nausea and vomiting. Data on its utility in reducing CINV in children and young adults are lacking. PATIENTS AND METHODS: Sixty chemotherapy cycles of cisplatin/doxorubicin in bone sarcoma patients were randomized to ginger root powder capsules or placebo capsules as an additional antiemetic to ondensetron and dexamethasone in a double-blind design. Acute CINV was defined as nausea and vomiting occurring within 24 hr of start of chemotherapy (days 1-4) and delayed CINV as that occurring after 24 hr of completion of chemotherapy (days 5-10). CINV was evaluated as per Edmonton's Symptom Assessment Scale and National Cancer Institute criteria respectively. RESULTS: Acute moderate to severe nausea was observed in 28/30 (93.3%) cycles in control group as compared to 15/27 (55.6%) cycles in experimental group (P = 0.003). Acute moderate to severe vomiting was significantly more in the control group compared to the experimental group [23/30 (76.7%) vs. 9/27 (33.33%) respectively (P= 0.002)]. Delayed moderate to severe nausea was observed in 22/30 (73.3%) cycles in the control group as compared to 7/27 (25.9%) in the experimental group (P < 0.001). Delayed moderate to severe vomiting was significantly more in the control group compared to the experimental group [14/30 (46.67%) vs. 4/27 (14.81%) (P = 0.022)]. CONCLUSION: Ginger root powder was effective in reducing severity of acute and delayed CINV as additional therapy to ondensetron and dexamethasone in patients receiving high emetogenic chemotherapy (ClinicalTrials.gov identifier: NCT00940368).